|
UNITED STATES
|
|
SECURITIES AND EXCHANGE COMMISSION
|
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported) – May 23, 2012
|
WEST PHARMACEUTICAL SERVICES, INC.
|
(Exact name of registrant as specified in its charter)
|
Pennsylvania
|
1-8036
|
23-1210010
|
||
|
(State or other jurisdiction
of Incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
||
|
101 Gordon Drive, PO Box 645, Lionville, PA
|
19341-0645
|
|||
|
(Address of principal executive offices)
|
(Zip Code)
|
|||
Registrant’s telephone number, including area code: 610-594-2900
|
Not Applicable
|
|
(Former name or address, if changed since last report)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01. Regulation FD Disclosure
On May 23, 2012, West Pharmaceutical Services, Inc. (the “Company”) will host an Analyst and Investor Day from 8:30 to 11:30 AM EDT in New York, New York. Members of the Company’s senior management will provide an overview of the company’s current markets, operations, and growth opportunities at 9:00 AM EDT.
A copy of the Company’s presentation materials from the Investor Day will be available for 30 days through the Investors link at the Company’s website, http://www.westpharma.com, and is also attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (Exchange Act) or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.
Item 9.01. Financial Statements and Exhibits
|
(d)
|
Exhibits
|
|
|
Exhibit 99.1
|
West Pharmaceutical Services, Inc. Overview (Investor Presentation).
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
WEST PHARMACEUTICAL SERVICES, INC.
|
|
/s/ John R. Gailey III
|
|
John R. Gailey III, Vice President, General
|
|
Counsel and Secretary
|
May 23, 2012
3
EXHIBIT INDEX
|
Exhibit No.
|
Description
|
|
|
99.1
|
West Pharmaceutical Services, Inc. Overview (Investor Presentation).
|
4